
Opinion|Videos|May 29, 2025
Nonimmune Adverse Effects: Managing Dysgeusia and Fatigue
Panelists discuss how the assessment and management of immune effector cell–associated neurotoxicity syndrome involves grading symptoms from mild to life-threatening, emphasizing the need for prompt recognition and rapid intervention to prevent progression and minimize long-term neurological damage.
Advertisement
Episodes in this series

Summary for Physicians:
Nonimmune Adverse Effects: Managing Dysgeusia and Fatigue
- Dysgeusia (altered taste):
- Common adverse effect, particularly with chemotherapy and immunotherapy
- Management:
- Recommend small, frequent meals with strong flavors (eg, citrus, mint).
- Suggest using plastic utensils to minimize taste alteration.
- Encourage good oral hygiene to reduce taste disturbances.
- Fatigue:
- Frequently reported, can be persistent and impact quality of life
- Management:
- Energy conservation techniques (eg, rest periods, prioritizing tasks)
- Exercise programs to improve stamina and reduce fatigue
- Monitor for underlying causes such as anemia or dehydration
- Address sleep hygiene and manage emotional stress
Challenges:
Both symptoms can be challenging to manage long term, requiring personalized strategies and regular assessment.
Advertisement
Related to this article

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Martin Gleave, CM, MD, FRCSC, FACS, explained how the GUNS trial is using tumor genomics to guide neoadjuvant therapy in high-risk prostate cancer.

Daniel Y.C. Heng, MD, MPH, FRCPC, explained how subsequent therapy and durable responses may have shaped overall survival results in LITESPARK-011.

Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.

Arturo Loaiza-Bonilla, MD, MSEd, FACP, co-founder of Massive Bio and system-wide chief of hematology and oncology at St. Luke’s, explains how AI is matching patients to clinical trials, where the technology falls short, and why he left academia to build what oncology was missing.

The FDA granted RMAT and fast track designations to prizlon-cel, a CD20/CD19 CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.

Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
3
Managing Emergencies During Outpatient Bispecific Step-Up Dosing
4
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
5

